Navigation Links
Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Date:4/21/2009

SEATTLE, April 21 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the Company has enrolled the first patient in a Phase 1 clinical trial of D3263 in patients with advanced cancer. D3263 is Dendreon's lead small molecule drug candidate designed to target TRPM8 (a transmembrane cation channel protein) in cancer cells and induce cell death. The trial is an open-label, dose-escalation study evaluating the safety and pharmacokinetics of orally-administered D3263 in patients with solid tumors that are refractory to standard therapies.

The Phase 1 trial will enroll three to six patients per cohort during the dose escalation phase of the study. An expansion cohort may be enrolled following determination of the maximum tolerated dose. The primary endpoint of the study will be safety, but patients also will be evaluated for anti-tumor activity as well as tolerance of the drug in order to determine the optimal schedule and level of dosing. The trial has been initiated at South Texas Accelerated Research Therapeutics (START) in San Antonio Texas under the direction of Dr. Anthony W. Tolcher.

"D3263 is a drug candidate that has potential applicability to multiple types of cancer as well as to benign prostatic hyperplasia (BPH)," stated Mark Frohlich, M.D., senior vice president of clinical affairs and chief medical officer of Dendreon. "The ability of D3263 to inhibit growth of TRPM8 expressing tumors in preclinical studies coupled with its oral bioavailability make it an appealing product candidate to advance into human clinical trials."

Patients interested in additional information about this trial may visit www.clinicaltrials.gov and use the search term "D3263."

About TRPM8

TRPM8 (also known a
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
10. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
11. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... Feb. 9 Delcath ... medical technology company testing its proprietary treatment system ... announced today the signing of its first research, ... Hepatic Perfusion (PHP) System  (the Delcath PHP System™). ... exclusive right to market and sell the Delcath ...
(Date:2/9/2010)... , Feb. 9 Palatin ... announced the completion of first cohort dosing in ... experimental treatment for sexual dysfunction.  The primary endpoint ... blood pressure effects of subcutaneous bremelanotide in men ... will also evaluate consistency of plasma exposure of ...
(Date:2/8/2010)... Calif. , Feb. 8 PreXion, ... quality 3D Cone Beam Imaging systems for dentistry, today ... as Director of Marketing. ,, PreXion President/COO ... Keith on our senior management team and I look ... extensive sales and marketing leadership, experience and success in ...
Breaking Medicine Technology:Delcath Signs First Partner Agreement in Asia 2Delcath Signs First Partner Agreement in Asia 3Delcath Signs First Partner Agreement in Asia 4Delcath Signs First Partner Agreement in Asia 5Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 2Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 3Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 4PreXion, Inc. Announces Appointment of Director of Marketing 2BayCare Named CIO 100 Award Winner by CIO Magazine 47458 1BayCare Named CIO 100 Award Winner by CIO Magazine 47458 2BayCare Named CIO 100 Award Winner by CIO Magazine 47458 3NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 1NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 2NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 3FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 1FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 2FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 3FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 4FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 5FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 6FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 7
... - Research Collaboration to ... Jubilant Organosys Ltd, headquartered in ... Biosys Ltd, has signed a research,collaboration agreement with, ... the international pharmaceutical company,s pre-clinical,pipeline. Under the shared ...
... concludes that new cosmeceutical improves skin barrier function, erythema ... Senetek PLC (OTC Bulletin Board: SNKTY), ... technologies that target the science of healthy aging, today ... Lotion for Improving the Signs and Symptoms of Rosacea," ...
Other Medicine Technology:Jubilant Enters Research Collaboration With AstraZeneca 2Jubilant Enters Research Collaboration With AstraZeneca 3Jubilant Enters Research Collaboration With AstraZeneca 4Spotlight on Rosacea Advance - May Issue of Journal of Drugs in Dermatology Features Pyratine XR(TM) Clinical Study 2
(Date:2/9/2010)... much more weight than peers who tried lifestyle changes ... teens who received gastric banding surgery lost significantly more ... dieting and exercise, Australian researchers report. , Their study ... body-mass index (BMI) higher than 35 (statistical obesity begins ... gastric banding while the other half took part in ...
(Date:2/9/2010)... likely to insert them , , TUESDAY, Feb. 9 (HealthDay ... up to make a profit are more likely to ... evidence that the practice does not prolong life or ... results suggest that decisions about feeding tubes are more ... process that really elicits and supports patient choice," said ...
(Date:2/9/2010)... The nation,s fourth leading cause ... now being measured by the Minnesota Department of ... focuses on three major causes of hospitalizations in ... made worse by environmental factors such as secondhand ... attacks and COPD. ,, The report indicates ...
(Date:2/9/2010)... Give a Gift for ... ,, CHICAGO , Feb. 9 ... by giving a gift for the ... Fresh, Fast, and Flavorful Recipes Made with Canola Oil" ... you cook some of these recipes for love or ...
(Date:2/9/2010)... In conjunction with the 2010 Super Bowl, ... (LSI) sponsored the first-annual Gridiron Greats Night of Champions, a ... Mike Ditka and Jamie Foxx . Supported ... Greats is a non-profit organization that provides financial assistance and ... This year, Gridiron Greats recognized LSI at the event as ...
Breaking Medicine News(10 mins):Health News:Gastric Banding Most Effective for Obese Teens 2Health News:Too Many With End-Stage Dementia Get Feeding Tubes 2Health News:Too Many With End-Stage Dementia Get Feeding Tubes 3Health News:Minnesota Department of Health Report: Nearly 6,000 Hospitalizations for COPD in 2007 2Health News:Cook With Love This Valentine's Day With Heart-Smart Recipes 2Health News:Cook With Love This Valentine's Day With Heart-Smart Recipes 3Health News:Laser Spine Institute Honored at the Gridiron Greats Night of Champions 2
... . , May 29 Landauer, Inc. (NYSE: ... named Chief Nuclear Executive, effective May 15, 2009. Gipson ... "We are very pleased to be able to name ... industry experience at the executive and operating level and will ...
... The British Red Cross are asking people,to pledge their ... social networks, instant messenger and email during,Refugee Week (15th-21st June). ... that a charity has created an online movement to,pledge support ... Refugees arriving in the UK are often labelled as ...
... urges president to learn from their proven preventive approach to solve ... ... (PRWEB) May 29, 2009 -- Cenegenics® Medical Institute, global age management ... a White House interview that he,s "absolutely committed" to a healthcare ...
... First in a Series of Community Discussions on Improving ... 28 Teva Pharmaceuticals USA, the leading generic pharmaceutical ... community roundtables as part of their Year of Affordable ... held at the YMCA San Francisco, aimed at raising ...
... the UltraPulse CO2 fractional laser as a Miracle Treatment for Burn ... will also be featuring the treatment tonight, check your local listings ... by The Insider . The interview focused on how and ... years. The girls also discussed their journey through the treatment process ...
... Nuvilex, Inc. (OTC Bulletin Board: NVLX), an emerging ... 41 Direct, Inc. (CK41), the Company,s joint venture marketing ... updated its product launch plans. The previously announced mid-May ... Savage, CK41,s new Chief Executive Officer, to impart his ...
Other Medicine News:Health News:Landauer Names Douglas R. Gipson Chief Nuclear Executive 2Health News:Global Creative, Media and Technology Agency LBi Launches Cutting Edge Social Movement for the British Red Cross in Support of Refugee Week 2Health News:Cenegenics Poses Challenge to Obama for Successful Healthcare Reform 2Health News:Cenegenics Poses Challenge to Obama for Successful Healthcare Reform 3Health News:Cenegenics Poses Challenge to Obama for Successful Healthcare Reform 4Health News:The Year of Affordable Healthcare Brings Together San Francisco Community Groups to Tackle Healthcare Crisis 2Health News:Miracle Treatment for Burn Scars as Seen on Today Show Will Also Be Featured on The Insider Tonight 2Health News:Miracle Treatment for Burn Scars as Seen on Today Show Will Also Be Featured on The Insider Tonight 3Health News:Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan 2Health News:Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan 3Health News:Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan 4
... many years experience in the field of Urodynamics, ... Urodynamics Chair. Our new chair is manufactured from ... of Urodynamic studies can be improved considerably if ... the test, and this aspect was given a ...
The Triage Drugs of Abuse Panel is the leading rapid drug screen used by U.S. hospitals. The Triage Drugs of Abuse Panel is a small, handheld urine test that provides qualitative results for up to n...
... The Advanced Model 3900 Multi-Sample ... for laboratories processing moderate to high ... industry-preferred method of freezing-point technology for ... combined with high, continuous throughput, the ...
... Osmometer provides extremely accurate osmolality measurements ... These results are obtained by using ... total concentration. Only the model 2020 ... sample handling, and flexible reporting options ...
Medicine Products: